Kronox Lab FY26 Net Profit Rises, Declares Dividend

Kronox Lab Sciences Limited has announced its audited standalone financial results for the quarter and year ended March 31, 2026. The company reported a net profit of ₹800.21 lakh for the quarter ended March 31, 2026, compared to ₹631.52 lakh in the corresponding quarter of the previous year. For the full financial year, the net profit stood at ₹2,766.00 lakh, an increase from ₹2,546.70 lakh in FY25.

Financial Performance

The revenue from operations for the year ended March 31, 2026, was ₹10,122.00 lakh, compared to ₹10,019.40 lakh in the previous year. Total income for the year rose to ₹10,641.40 lakh from ₹10,272.00 lakh in the prior year. The company's earnings per share (EPS) for the year increased to ₹7.51 from ₹6.91 in the previous year.

Metric	Year Ended March 31, 2026 (₹ in Lacs)	Year Ended March 31, 2025 (₹ in Lacs)
Revenue from Operations	10,122.00	10,019.40
Total Income	10,641.40	10,272.00
Net Profit	2,766.00	2,546.70
EPS (Basic & Diluted)	7.51	6.91

Dividend Declaration

The Board of Directors has recommended a final dividend of 5%, which translates to ₹0.50 per equity share of ₹10 each, for the financial year 2025-26. This dividend is subject to the approval of shareholders.

Regulatory Compliance

Pursuant to Regulation 47 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the company published the audited financial results in newspapers on May 23, 2026. The results were reviewed by the auditors, recommended by the Audit Committee, and approved by the Board in its meeting held on May 21, 2026. The statutory auditors, M/s. Mahesh Udhwani & Associates, issued an audit report with an unmodified opinion.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-3.23%	+15.09%	+16.28%	+6.39%	-8.60%	-3.99%

KRONOX Lab Sciences Limited has issued a regulatory clarification to stock exchanges regarding significant movement in its share price, stating that the company is not aware of any specific reasons behind the price fluctuation. The clarification was submitted on April 08, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Compliance Statement

In its filing to both National Stock Exchange of India Limited and BSE Limited, the company emphasized its consistent adherence to disclosure requirements. The management stated that it has always been disclosing all material information that has a bearing on the company's operations and performance, including price-sensitive information and other necessary disclosures within stipulated timeframes.

Exchange Details:	Information
NSE Scrip Symbol:	KRONOX
BSE Scrip Code:	544187
Filing Date:	April 08, 2026
Regulation:	SEBI Regulation 30

Management Position on Price Movement

The company's management clarified that it is not connected with the movement in share prices and attributed the fluctuation to market-driven factors. Company Secretary and Compliance Officer Nikhil Goswami, who signed the clarification, reiterated the company's commitment to maintaining compliance with listing regulations and other applicable laws.

Corporate Information

KRONOX Lab Sciences Limited operates from its corporate office in Block No. 284, Village Dabhasa, Taluka Padra, District Vadodara, Gujarat State. The company's registered office is located at Block No. 353, Village Ekalbara in the same taluka and district. The company maintains its commitment to transparency and regulatory compliance as outlined in the SEBI listing regulations.